» Articles » PMID: 32862133

Cytosine Arabinoside Constant Rate Infusion Without Subsequent Subcutaneous Injections for the Treatment of Dogs with Meningoencephalomyelitis of Unknown Origin

Overview
Journal Vet Rec
Publisher Wiley
Date 2020 Aug 31
PMID 32862133
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The administration of cytosine arabinoside (CA) by continuous rate infusion (CRI) at the time of diagnosis has been shown to improve the 3-month survival of dogs diagnosed with meningoencephalomyelitis of unknown origin (MUO), compared to subcutaneous administration. The benefit of administering subsequent sequential CA subcutaneous injections is unknown. This study compares the outcomes of a CA CRI protocol with (CRI+subcutaneous group) or without (CRI group) follow-up CA subcutaneous injections; both groups received adjunctive prednisolone.

Methods: Forty-two dogs diagnosed with MUO were recruited (CRI group) and compared with 41 historical control dogs (CRI+subcutaneous group) in a prospective, controlled clinical trial with 36 months of follow-up.

Results: Success rates were respectively 64.3 per cent and 65 per cent in the CRI and the CRI+subcutaneous groups at 40 weeks following diagnosis, and 32.5 per cent and 35.9 per cent at 36 months following diagnosis. The median time to relapse was 299 and 285 days for the CRI and the CRI+subcutaneous groups, respectively. No statistically significant difference was found (P≥0.05).

Conclusion: No clear benefit was identified in the administration of subsequent sequential CA subcutaneous injections after the first administration of CA by CRI for the treatment of dogs diagnosed with MUO.

Citing Articles

Breed-Specific Clinical Features, Diagnostic Findings, and Outcome of Presumptive Meningoencephalomyelitis of Unknown Origin in 27 French Bulldogs.

Burbaite E, Fiorentino E, Galli G, Gallucci A, Tirrito F, Gandini G Vet Sci. 2025; 12(2).

PMID: 40005843 PMC: 11861780. DOI: 10.3390/vetsci12020083.


Clinical features, treatment, and outcome of juvenile dogs with meningoencephalitis of unknown etiology.

Galer J, Forward A, Hughes J, Crawford A, Behr S, Cherubini G J Vet Intern Med. 2024; 38(4):2214-2220.

PMID: 38932495 PMC: 11256174. DOI: 10.1111/jvim.17126.


Survival in dogs with meningoencephalomyelitis of unknown etiology with and without lesions detected by magnetic resonance imaging.

Ostrager A, Bentley R, Lewis M, Moore G J Vet Intern Med. 2024; 38(4):2204-2213.

PMID: 38804716 PMC: 11256124. DOI: 10.1111/jvim.17109.


Prognosis in meningoencephalitis of unknown origin in dogs: Risk factors associated with survival, clinical relapse, and long-term disability.

Goncalves R, De Decker S, Walmsley G, Maddox T J Vet Intern Med. 2024; 38(3):1583-1590.

PMID: 38483069 PMC: 11099754. DOI: 10.1111/jvim.17037.


Retrospective evaluation of prognosis and survival with various immunosuppressants in 82 dogs diagnosed with meningoencephalitis of unknown etiology (2010-2021).

Kim S, Oh Y, Park S, An J, Kim T, Kim S BMC Vet Res. 2023; 19(1):269.

PMID: 38087262 PMC: 10714563. DOI: 10.1186/s12917-023-03800-3.